What question did this study set out to answer?

To review emerging treatment strategies in first-line approaches for mantle cell lymphoma.

November 17, 2025Leukemia & lymphoma/Leukemia and lymphoma

Emerging first-line treatment approaches for mantle cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

CDChangchun Deng NANikki Agarwal ASAriel D. Sindel

Discussion

Member takes

Implication

This review highlights the impact of BTK inhibitors in first-line treatment of mantle cell lymphoma, suggesting improved outcomes in high-risk patients with TP53 alterations.

Key Points

To review emerging treatment strategies in first-line approaches for mantle cell lymphoma.
Analysis of recent clinical trials focused on BTK inhibitors and their combinations.
Evaluation of treatment effectiveness in patients with TP53 alterations.
Review of the role of autologous stem cell transplant in modern treatment regimens.
BTK inhibitors like acalabrutinib and ibrutinib show high effectiveness in front-line therapy.
Combination therapies with venetoclax improve outcomes for high-risk mantle cell lymphoma.
Autologous stem cell transplant may not add benefits in patients already receiving effective first-line treatments.

Cite This Study

Deng et al. (2025) studied this question.

synapsesocial.com/papers/692509f6c0ce034ddc352c2c https://doi.org/10.1080/10428194.2025.2586079

View Full Paper

Ask AI

Bookmark

Implication

This review highlights the impact of BTK inhibitors in first-line treatment of mantle cell lymphoma, suggesting improved outcomes in high-risk patients with TP53 alterations.

Emerging first-line treatment approaches for mantle cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Emerging first-line treatment approaches for mantle cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider